These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32708835)

  • 1. Economic Evaluation of Population-Based
    Manchanda R; Sun L; Patel S; Evans O; Wilschut J; De Freitas Lopes AC; Gaba F; Brentnall A; Duffy S; Cui B; Coelho De Soarez P; Husain Z; Hopper J; Sadique Z; Mukhopadhyay A; Yang L; Berkhof J; Legood R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
    Sun L; Cui B; Wei X; Sadique Z; Yang L; Manchanda R; Legood R
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
    Lipton JH; Zargar M; Warner E; Greenblatt EE; Lee E; Chan KKW; Wong WWL
    Hum Reprod; 2020 Feb; 35(2):434-445. PubMed ID: 32099994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
    Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
    JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    Lim KK; Yoon SY; Mohd Taib NA; Shabaruddin FH; Dahlui M; Woo YL; Thong MK; Teo SH; Chaiyakunapruk N
    Appl Health Econ Health Policy; 2018 Jun; 16(3):395-406. PubMed ID: 29572724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
    J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    Hurry M; Eccleston A; Dyer M; Hoskins P
    Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
    Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
    Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
    Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
    Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    Michaelson-Cohen R; Cohen MJ; Cohen C; Greenberg D; Shmueli A; Lieberman S; Tomer A; Levy-Lahad E; Lahad A
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility analysis of
    Lertwilaiwittaya P; Tantai N; Maneeon S; Kongbunrak S; Nonpanya N; Hurst ACE; Srinonprasert V; Pithukpakorn M
    Front Public Health; 2023; 11():1257668. PubMed ID: 38162618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Hoskins P; Eccleston A; Hurry M; Dyer M
    Gynecol Oncol; 2019 Apr; 153(1):87-91. PubMed ID: 30704745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.